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Effect of transfection of a Drosophila topoisomerase II gene into a human
brain tumour cell line intrinsically resistant to etoposide
T Asanol, LA Zwelling2, T An', A McWatters', CE Herzog3, J Mayes2, SM Loughlin2 and
ES Kleinerman" 3
Departments of'Cell Biology, 2Medical Oncology and3Pediatrics, The University ofTexas M.D. Anderson Cancer Center, Houston,
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Summary The human brain tumour cell line HBT20 is intrinsically resistant to etoposide and does not express
mdr-1 mRNA. These studies were conducted to determine whether transfecting a Drosophila (D) topoisomerase
II (topo II) gene into HBT20 cells could increase their sensitivity to etoposide. A D-topo II construct in a
pMAMneo vector under the control of a mouse mammary tumour virus (MMTV) promoter was transfected
into HBT20 cells. The gene is inducible by dexamethasone (Dex). The growth rate of the transfected cells and
percentage of the cells in G,, S and G2M was no different than the parental cells. Survival after etoposide
exposure (10 gM x 2 h) was measured by colony formation. Parental cells and cells transfected by pMAMneo
vector alone showed no enhanced etoposide sensitivity after 24 h of Dex stimulation. By contrast, D-topo II
transfected cells were sensitised 3-fold when etoposide treatment was preceded by 24 h Dex stimulation.
Northern blotting and Western blotting confirmed that Dex had induced D-topo II expression in the sensitised
cells. However, in D-topo II-transfected cells increasing the duration of Dex stimulation to 48 h eliminated the
sensitisation to etoposide although increased MMTV promoter activity and expression of the D-topo II gene
persisted. Measurement of endogenous human topo-Il mRNA and protein revealed a decrease after Dex
exposure of greater than 24 h. At these distal times, the total cellular topo II levels (endogenous+exogenous)
may be decreased, which may explain why increased sensitivity to etoposide could no longer be demonstrated.
This model suggests that D-topo II gene transfection can sensitise de novo resistant HBT20 cells to etoposide
but that the time frame of that sensitisation is limited.
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Topoisomerase II, an essential nuclear enzyme, is a drug
target for the treatment of human cancers. Several of the
most active antineoplastic agents paralyse this enzyme by
stabilising a complex between the enzyme and the DNA
strands manipulated by it in the course of its normal function
(Wang, 1985; Liu, 1989; Zwelling, 1989). This stabilised
complex poisons the cell by initiating an apoptotic cell death
pathway whose biochemistry is not completely understood at
present.
Several cell systems that resist the cytotoxic actions of
topoisomerase II target drugs have been described. Either the
topoisomerase II within the cells resists stabilisation by the
drugs as a result of mutations in the coding sequences for the
enzyme (Zwelling et al., 1989; Bugg et al., 1991; Lee et al.,
1992; Chan et al., 1993; Champain et al., 1994) or the enzyme
levels are so low (Takano et al., 1991; Webb et al., 1991;
Ritke et al., 1994; Schneider et al., 1994) that the amount of
complex formed is insufficient to initiate cell death. Most of
these cell systems were developed by repeatedly treating the
cell lines and thus are examples of induced drug resistance.
By contrast, brain tumours are usually intrinsically resistant
to drug therapy, including agents that target topoisomerase
II.
We acquired a series of human brain tumour cell lines that
had not been exposed to cancer chemotherapeutic drugs
either in culture or as primary tumours within patients. These
tumours are often resistant to commonly used chemother-
apeutic agents. Because recent technology allows the
transfection of genes (Eder et al., 1993; Liu et al., 1994;
Wasserman and Wang, 1994) into brain tumours in situ, we
began a series ofexperiments that we hoped would eventually
lead to new approaches to clinical treatment of brain
tumours. Our goal was to sensitise human brain tumours to
topoisomerase II-directed agents by increasing the expression
of drug-sensitive topoisomerase II within these tumours. This
report describes our successful sensitisation of de novo
resistant human brain tumour cells to etoposide, an agent
commonly used for the treatment of paediatric tumours
(Bleyer, 1992).
Materials and methods
Reagents and drugs
Dulbecco's modified Eagle medium (DMEM), Hanks'
balanced salt solution without Ca21 or Mg2+ (HBSS), fetal
calf serum (FCS), gentamicin and L-glutamine were
purchased from Whittaker Bioproducts (Walkersville, MD,
USA). Anti-human topoisomerase II polyclonal antibody was
obtained from TopoGen (Columbus, OH, USA). Rabbit
anti-Drosophila topoisomerase II antiserum was a gift from
Dr N Osheroff (Vanderbilt University, Nashville, TN, USA).
Etoposide, a gift from Drs B Long and JH Keller of Bristol-
Myers (Syracuse, NY, USA) or purchased from Sigma Co.
(St Louis, MO, USA), was solubilised in dimethylsulphoxide
(DMSO). Amsacrine and cisplatin were obtained from the
National Cancer Institute (Bethesda, MD, USA). Doxorubi-
cin was a gift from Adria Laboratories (Columbus, OH,
USA).
Cell line
The human brain tumour cell line HBT20 was obtained from
Dr F Ali-Osman (Department of Experimental Pediatrics,
M.D. Anderson Cancer Center, Houston, TX, USA). This
cell line was established from a human brain tumour
specimen (pathological diagnosis glioblastoma multiforme)
resected from a patient who had received no previous
chemotherapy. The cells were cultured in DMEM with 10%
FCS, 2 mM glutamine and 50 ,Mg ml-' gentamicin (DIO
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medium). All cells were free of mycoplasma as screened
by Gen-Probe (Gen-Probe, San Diego, CA, USA) or the
American Tissue Culture Collection (Rockville, MD,
USA).
Transfection of tumour cells
The wild-type Drosophila topoisomerase II gene constructed
into the NheI site of a mammalian expression vector
containing a glucocorticoid-inducible mouse mammary
tumour virus (MMTV) promoter (pdTOP2MAMneo) was a
gift from Dr JP Eder Jr. (Harvard Medical School, Boston,
MA, USA) (Eder et al., 1993). Transfection was performed
24 h after seeding 105 cells per T-75 flask (Costar; Cam-
bridge, MA, USA) by calcium phosphate co-precipitation
with 20 pg of pdTOP2MAMneo or pMAMneo vector
(control). After 24 h of exposure at 37°C, co-precipitated
medium was removed and cells were maintained in Dl0
medium for 3 days. Cultures were then selected in G418
(0.8 mg ml-'; Gibco, Grand Island, NY, USA) and
expanded.
Because topoisomerse II expression is suppressed in
confluent cells (data not shown), the following experiments
were carried out with cells <70% confluence.
Northern blot analysis
An aliquot of 20 pg of total RNA was extracted and
electrophoresed, then transferred and hybridised with human
topoisomerase IIa gene probe, a gift from Dr L Liu (Robert
Wood Johnson Medical School, University of Medicine and
Dentistry of New Jersey, NJ, USA) (Zwelling et al., 1989) or
the SphI -NheI fragment of Drosophila topoisomerase II
cDNA. Densitometric analysis was performed using a
personal densitometer (Molecular Dynamics, Sunnyvale,
CA, USA) and values were normalised for differences in f,-
actin-scanning densities.
Immunoblotting
For detection of Drosophila topoisomerase II protein, the
nuclei extract method was used (Minford et al., 1986). Cells
were washed with nuclear buffer (150 mm sodium chloride
5 mM magnesium chloride, 2 mM potassium hydrogen
phosphate, 1 mM EGTA, 10% glycerol, 0.1 mM dithiothrei-
tol, 0.1 mM phenylmethylsulphonyl fluoride), then lysed by
incubation for 10 min in nuclei buffer with 0.3% Triton X-
100. Isolated nuclei were then extracted for 30 min in nuclei
buffer, with final sodium chloride concentration to 350 mM.
The nuclei were then centrifuged at 10 000 x g. Protein in the
supematant nuclei was measured using the BioRad method
(Richmond, CA, USA). For detection of human topoisome-
rase II protein, a modification of the method of Kaufmann et
al. (1991) was employed. Cells (1 x 107) from various
transfectants were incubated with or without 10 pM
dexamethasone, followed by sonication with 40 bursts at
60% power (Heat Systems-Ultrasonics, sonicator) in alkyla-
tion buffer [6 M guanidine-HCl, 250 mM Tris (pH 8.5),
10 mM disodium EDTA] with 1% 2-mercaptoethanol and
1 mM phenylmethylsulphonyl fluoride added. The reactions
were allowed to reduce overnight, after which 100 pl of 1.5 M
iodoacetamide in alkylation buffer was added to each 1.02 ml
sample and incubated for 1 h at room temperature; then,
10 pl of 2-mercaptoethanol was added. Each sample was
dialysed once for 90 min against 4 M urea, 50 mM Tris,
pH 7.4; four times for 90 min against 4 M urea; three times
for 90 min each against 0.1% SDS; and then was lyophilised
for storage. Samples were solubilised in SDS sample buffer
[4 M urea, 2% SDS, 62.5 mM Tris-HCl (pH 6.8), 1 mM
disodium EDTA] and electrophoresed in a 6% polyacryla-
mide gel. Immunoblotting was performed using ECL Western
blotting analysis system (Amersham, Arlington Heights, IL,
USA) according to the manufacturer's instruction with a
1: 500 dilution of rabbit anti-Drosophila topoisomerase II-
antiserum or anti-human topoisomerase II polyclonal anti-
body.
SDS-KCI precipitation assay
Cells (4 x 105) from each of the transfectants (with or without
dexamethasone pretreatment) were radiolabelled with
[3H]thymidine deoxyribose (TdR: ICN Biomedicals, Irvine,
CA, USA) and ['4C]leucine (Amersham) for 24 h at 37°C.
The cells were then washed and chased with medium for 1 h
before their incubation with DMSO or various concentra-
tions of etoposide for 1 h. The cells were lysed and the DNA
protein complexes precipitated as previously described
(Zwelling et al., 1989). The rate of topoisomerse TI-mediated
DNA relegation was measured using the methods of Hsiang
and Liu (1989).
Alkaline elution assay
The tumour cells were radiolabelled by incubation with
0.05 pCi ml-' [2-'4C]thymidine (Amersham) for one dou-
bling time, then chased for the same time period. Mouse
leukaemia L1210 cells, used as an internal standard in
alkaline elution assays, were radiolabelled with 0.1 pCi ml-'
[methyl-3H]thymidine for 16-20 h. Single-strand breaks were
quantified using proteinase K in the lysis step, then elution
at pH 12.1 at a rate of 0.15 ml min-' for 35 min as
previously described by Kohn et al. (1981). Non-protein
concealed breaks were detected without the use of proteinase
K at an elution rate of 2 ml h-' for 15 h.
Colonyformation assay
Expression of the Drosophila topoisomerase II gene was
induced by cell exposure to 10 pM dexamethasone for 4-48 h
before treatment with medium alone or etoposide (2 h). Cells
were then washed twice with phosphate-buffered saline (PBS),
re-fed with conditioned media (media removed from
subconfluent cells) and incubated for 24 h before trypsinisa-
tion and subcloning into fresh media. Colonies were allowed
to form for 12 days, then were stained with 0.04% crystal
violet in methanol and counted. The results were expressed as
survival fraction compared with the colony-forming efficiency
of the medium-treated control.
Chloramphenicol acetyltransferase (CAT) assay
Transfection of CAT constructs was carried out by calcium
phosphate co-precipitation with 20 pg of CAT constructs.
pMAMneo-CAT, which has MMTV promoter upstream of
the CAT gene, was obtained from Clontech (Palo Alto, CA
USA). After 24 h of exposure at 37°C, co-precipitated
medium was removed and the cells incubated with or
without 10 pM dexamethasone for 48 h or 72 h. The cells
were then harvested by scraping, suspended in 200 pl of
0.25 M Tris-HCl (pH 7.9) and lysed by three cycles of
freezing and thawing. Aliquots of 30 pl were heated to
65°C for 10 min to inactivate endogenous deacetylases and
incubated for 2 h at 37°C with 3 mM acetyl coenzyme A
(Sigma) and 0.05 pCi of [14C]deoxychloramphenicol (Amer-
sham). The products were extracted with ethyl acetate and
acetylated products were suspended in thin-layer chromato-
graphy plates (Eastman Kodak, Rochester, NY, USA). The
plates were then exposed to radiographic film.
Cell cycle analysis
Aliquots of 1 x 106 HBT20-parent, HBT20-MAM and
HBT20-dTOP2MAM treated with medium or Dex were
washed with PBS, fixed with ethanol, resuspended in PBTB
(0.5% Tween-20, 0.5% bovine serum albumin in PBS) with
0.01% RNAase and incubated for 30 min at 37°C. The cells
were then stained with 0.1% propidium iodine and the
fluorescence distributions were measured by flow cytometer.Transfection of D-topolla into human brain tumour cells
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Results
Characterisation of HBT20 cell sensitivity to etoposide
HBT20 cells are intrinsically resistant to the cytotoxic action
ofetoposide. The IC50 ofetoposide was 13 ,UM (2 h exposure).
This resistance was not due to mdr-I expression, as HBT20
cells do not express this message (data not shown). Resistance
could also not be explained by impaired intracellular uptake
of etoposide (Herzog et al., 1995). Furthermore, single-strand
conformation polymorphism (SSCP) analysis of the topoi-
somerase Ila message within these cells revealed no mutations
at sites known to harbour such resistance-associated sequence
changes. (M Danks, Department of Biochemical and Clinical
Pharmacology, St Jude Children's Research Hospital,
Memphis, TN, USA, Personal communication).
Expression ofDrosophila topoisomerase II gene in HBT20
These HBT20 cells were transfected with pMAMneo vector
or with the same vector containing the Drosophila topoi-
somerase II (D-topo II) used by Eder et al. (1993) to sensitise
Chinese hamster ovary (CHO) cells that had been induced to
epipodophyllotoxin resistance. This places the D-topo II gene
under the control of a dexamethasone-inducible promoter
(Eder et al., 1993).
HBT20 cells transfected with the D-topo II gene (HBT20-
dTOP2) but not exposed to dexamethasone exhibited a small
level of D-topo II mRNA expression. However, this
expression increased significantly after 24 h exposure to
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Figure 1 Northern blot analysis of HBT20-parent, HBT20-
MAM and HBT20-dTOP2 cells following their exposure to
dexamethasone. After a 24h incubation without (-) or with
(+) 1O UM dexamethasone, total RNA was extracted and
hybridised with Drosophila topoisomerase II probe, human
topoisomerase Ila probe (ZI169) or a fl-actin probe. Molecular
weights (arrows) were calculated from 28S and 18S bands by
ethidium bromide staining. The experiment shown is one
representative experiment of three. (a) Drosophila topoisomerase
II probe. (b) Human topoisomerase II probe. (c) ,B-actin probe.
(d) Densitometric analysis of human topoisomerase IIa gene
expression. After normalisation by ,B-actin density, relative density
was calculated. The values are the mean+ 1 s.d. from three
independent experiments.
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Figure 2 Time course of D-topo II mRNA expression in
HBT20-dTOP2 cells following dexamethasone exposure. HBT20-
dTOP2 cells were incubated for 6, 12, 18, 24 and 48h with or
without dexamethasone (10/M). The cells were harvested and the
RNA extracted and hybridised with Drosophila topoisomerase II
probe, human topoisomerase Ila probe or ,B-actin probe.
Molecular weights (arrows) were calculated from 28S and 18S
bands by ethidium bromide staining. The experiment shown is
one representative experiment of three. (a) Drosophila topoisome-
rase II probe. (b) Human topoisomerase II probe. (c) ,B-actin
probe. (d) Densitometric analysis of Drosophila topoisomerase II
and human topoisomerase II gene expression. After normalisation
by ,B-actin density, the relative density in cells with dexametha-
sone at each time point was calculated by dividing the density in
the cells without dexamethasone. The values are the mean+ s.d.
from three independent experiments.
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dexamethasone (Figure 1). These results are consistent with
those of Eder et al. (1993). Along with the induction of the
transfected gene, the expression of the intrinsic human
topoisomerase II (H-topo II) gene unexpectedly decreased
(Figure 1). Examination of the time course of these events
revealed that the dexamethasone-induced expression of the
D-topo II gene appeared as early as 6 h after dexamethasone
addition and persisted for at least 48 h (Figure 2). The
associated decrease in endogenous H-topo II expression
required slightly longer to detect (12 h, Figure 2b and d)
but also persisted for 48 h. HBT20-parent and HBT20-MAM
control cells showed no significant change in H-topo II gene
expression with/without dexamethasone treatment for up to
48 h (Figure lb, data not shown).
Effect of D-topo II expression on levels of D-topo II and H-
topo II protein
The results of immunoblotting analysis using antibodies to
the D-topo II and H-topo II were consistent with the RNA
results. In those cells that contained the D-topo II gene and
were exposed to dexamethasone for 24 h, D-topo II protein
was detected and the amount of immunoreactive H-topo II
was decreased (Figure 3a and b).
DNA protein complexformation and DNA single-strand breaks
produced by etoposide in HBT20-dTOP2 cells
Indirect methods were used to assess whether D-topo II was
increasing the action of topoisomerase II most closely related
to etoposide cytotoxicity, that is production of topoisomerase
II-DNA complexes following exposure of cells to etoposide.
Small increases (20%) in etoposide-induced DNA protein
cross-link formation (Table I) or etoposide-induced DNA
cleavage (Table II) were seen. However, these were not
significant.
Effect ofDrosophila topoisomerase II gene expression on the
sensitivity of HBT20 cells to etoposide and other cancer
chemotherapeutic agents
Despite the relatively minor effect of the expression of
exogenous topoisomerase II on the biochemical correlates of
topoisomerase II drug sensitivity, the HBT20-dTOP2 cells
were significantly more sensitive to the cytotoxic actions of
10 gM etoposide following gene induction with Dex (Figure
4a). The lack of difference between the survival of transfected
and non-transfected cells at the high dose of etoposide
(50 gM) may simply result from the loss of assay sensitivity at
high drug concentrations. Dex treatment did not alter the
sensitivity ofHBT20-parent or HBT20-MAM cells (Figure 4b
and c). Furthermore, the transfection process did not by itself
alter etoposide sensitivity since the clonogenic survival of
HBT20-parent, HBT20-MAM, and HTB20-dTOP2 without
Dex treatment was not statistically different (Figure 4d).
Careful analysis of this effect at different times following gene
induction (dexamethasone treatment) revealed that the 24 h
time point was the one at which maximum sensitisation
occurred (Table III). After that point in time, sensitisation
diminished. This was not due to a loss of dexamethasone
Table I DNA-protein precipitable comple
chloride
responsiveness by the MMTV promoter, as this persisted for
at least 72 h (Figure 5). The increased sensitivity of HBT20-
dTOP2 Dex-treated cells was limited to etoposide and did not
extend to the topoisomerase II-reactive agent amsacrine
(Table IV). This may be because of the relative insensitivity
of Drosophila topo II to amsacrine compared with its
sensitivity to etoposide (Robinson and Osheroff, 1991). The
sensitivity of human and Drosophila topo II to etoposide is,
by contrast, similar. The transfected cells also did not show
an increased sensitivity to the DNA cross-linking agent
cisplatin or to doxorubicin which kills cells via other
mechanisms in addition to that involving topo II.
Cell cycle and cell growth analysis
Cell cycle analysis showed no significant difference in HBT20-
parent, HBT20-MAM and HBT20-dTOP2 cells either with or
without dexamethasone treatment for 24 h (Table V). Cell
growth analysis showed that the mean doubling time with
standard deviation was 33+3 h in HBT20-parent cells
without Dex and 32 +2 h with Dex; 33 +5 h in HBT20-
166 kDa
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Figure 3 Drosophila (a) and human topoisomerase II protein (b)
levels in HBT20-parent, HBT20-MAM and HBT20-dTOP2 cells.
Cells were treated with or without dexamethasone for 24h.
Drosophila and human topoisomerase II protein was then assayed
by immunoblot. Lane 1, HBT20-parent treated without
dexamethasone for 24h; lane 2, HBT20-parent treated with
dexamethasone for 24h; lane 3, HBT20-MAM treated without
dexamethasone for 24h; lane 4, HBT20-MAM treated with
dexamethasone for 24h; lane 5, HBT20-dTOP2 treated without
dexamethasone for 24h; lane 6, HBT20-dTOP2 treated with
dexamethasone for 24h.
formation assessed by SDS-potassium
HBT20-MAM HBT20-MAM HBT20-dTOP2 HBT20-dTOP2
VP-16 (#M) Dex (-) Dex (+) Dex (-) Dex (+)
10 4.0+0.2 3.2+0.4 4.0+0.3 4.7+0.3
50 6.6+0.1 4.9+0.5 6.5+1.1 6.0+0.2
Values areexpressed as a ratio of[3H]thymidine to[14C]leucine inetoposide-treated cells
divided by the [3H] to [14C] ratio of untreated cells with or without 24h dexamethasone
treatment. The values are the mean+1 s.d. from three independent experiments.Transfection of D-topolia into human brain tumour cells
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Table II DNA single-strand cleavage in HBT20 cellsa
Dex (-) Dex (+)
HBT20-parent 253+25b 268+ 19
HBT20-MAM 256+20 193+46
HBT20-dTOP2 268+ 15 292+ 5
aHBT20-parent, HBT20-MAM and HBT20-dTOP2 cells were
either treated with dexamethasone for 24h or remained untreated.
Then the cells were treated with 10 M etoposide for 1 h. The DNA
single-strand cleavage frequency was quantified using the alkaline
elution method with proteinase (see Materials and methods). brad
equivalent. The values are means+s.d. from three independent
experiments.
b
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Figure 4 Clonogenic survival in HBT20-parent, HBT20-MAM and HBT20-dTOP2 cells. Cells were pretreated with or without
dexamethasone for 24h before a 2h etoposide exposure. The values are the mean ± 1 s.d. from five independent experiments.
MAM without Dex and 31+5 h with Dex; 30+2 h in
HBT20-dTOP2 without Dex and 32 +4 h with Dex (data
from three independent experiments).
Discussion
The present study demonstrated that transfection of the
Drosophila topoisomerase II gene into human brain tumour
cells increased the sensitivity of these cells to the cytotoxic
actions of the topoisomerase II inhibitor etoposide. The
Drosophila topoisomerase II gene was in a mammalian
expression vector controlled by a dexamethasone-inducible
mouse mammary tumour virus promoter (Eder et al., 1993).
When the pdTOP2MAMneo vector was transfected into
HBT20 human brain tumour cells, expression of D-topo II
mRNA and protein was demonstrated following treatment of
the cells with dexamethasone (Figures 1 and 3) and
sensitisation to 10 giM etoposide increased 3-fold. Thus, the
increased sensitivity of the cells correlated with the induction
and expression of the D-topo II gene (Table III). As
previously described (Eder et al., 1993), this expression
a
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Table III Clonogenic survival of HBT20-MAM and HBT20-dTOP2 cells following etoposide
after various durations of exposure to dexamethasone
HBT20-MAM HBT20-MAM HBT20-dTOP2 HBT20-dTOP2
Dex treatment (-) (+) (-) (+)
4h 0.81 +0.03 0.68+0.12 0.77+0.05 0.60+0.19
12h 0.79+0.11 0.76+0.16 0.75+0.09 0.43+0.06*
24h 0.51+0.05 0.63+0.14 0.67+0.1 0.22+0.1*
48 h 0.58+0.09 0.71+0.2 0.74+0.16 0.78+0.08
72h 0.42+0.01 0.54+0.03 0.48+0.08 0.48+0.01
1 week 0.50+0.01 0.44+0.12 0.61+0.27 0.72+0.03
HBT20-MAM and HBT20-dTOP2 cells were pretreated with or without dexamethasone for4,
12, 24, 48 and 72h and 1 week. Dexamethasone was replaced every 48h. After dexamethasone
treatment, cellswereexposed to 10 uMetoposide for 2h. Survivalfractioniscalculated as stated in
Materials and methods. Thevalues are mean+s.d. from three independent experiments. P-values
were calculated by the Student's t-test. *P<0.05; Dex treatment (-) vs Dex treatment (+).
1 2 3 4 5 6
Figure 5 The effect of dexamethasone on transfected pMAM-
neo-CAT in HBT20 cells. Cells were transfected with CAT
downstream from the MMTV promoter (pMAMneo-CAT) Lane
1, FBS with 10/IM dexamethasone without transfection of CAT
construct; lane 2, CAT construct without MMTV promoter, with
FBS and dexamethasone; lane 3, pMAMneo-CAT with FBS
without 1O UM dexamethasone for 48h; lane 4, pMAMneo-CAT
with FBS and 1OgM dexamethasone for 48h; lane 5, pMAMneo-
CAT with FBS without 10 M dexamethasone for 72h; lane 6,
pMAMneo-CAT with FBS and 10 M dexamethasone for 72h.
system was not absolutely conditional as small basal levels of
D-topo II mRNA were detected in the absence of
dexamethasone (Figure 1).
HBT20 cells were established from a brain tumour
specimen from a patient who had not received prior
chemotherapy. These cells were not selected for in vitro
drug resistance, but they were relatively resistant to etoposide
with an IC50 of 13 juM following a 2 h exposure and an IC50
of 61 jpM following a 1 h exposure. Thus, we define these cells
as displaying de novo resistance to etoposide. The aetiology of
this resistance is not well understood. Herzog et al. (1995)
have shown that altered etoposide uptake, H-topo II protein
levels and H-topo II enzyme activity did not mechanistically
explain the resistance. Additionally, no previously defined H-
topo II mutations were identified by SSCP analysis. (M
Danks, personal communication). It is therefore intriguing
that transfection of a normal topo II gene onto a presumed
normal topo II background altered the sensitivity of these
cells. Previous investigations have been limited either to
transfecting a normal gene into a mutated background to
alter drug sensitivity or to transfecting the topoisomerase II
gene into a cell in which the endogenous topoisomerase II
gene could be inactivated by increasing the temperature (Eder
et al., 1993; Liu et al., 1994; Wasserman and Wang, 1994).
Induction of D-topo II mRNA expression was observed as
early as 6 h following stimulation with dexamethasone. This
enhanced expression of D-topo II continued for as long as
48 h (Figure 2). Enhanced sensitivity to etoposide could be
detected after 12 and 24 h, but not at time points greater
than 24 h (Table III). Thus, at a time point when D-topo II
was still being expressed (48 h), increased sensitivity to
etoposide was lost.
Etoposide targets the enzyme topo II and stabilises the
topo 1I-DNA complex. This complex is toxic to the cell. Our
hypothesis was that the HBT20-dTOP2 cells were producing
more topo II enzyme following dexamethasone stimulation,
which resulted in more complex formation after etoposide
treatment and increased cell kill. However, more complex
formation was not seen in these sensitised transfected cells.
This lack of concordance between etoposide-induced
cytotoxicity and etoposide-induced DNA cleavage can
perhaps be explained by the hypothesis recently proposed
by Gerwirtz (1991). He has proposed that the site rather than
the amount of drug-induced, topo II-mediated DNA cleavage
dictates the cytotoxicity of any given drug treatment. It is
likely that the DNA sites at which the transfected Drosophila
enzyme act are not identical to those at which the
endogenous human topoisomerase II act (Spitzner and
Muller, 1988). At low concentrations of etoposide, this
would mean new DNA sites would be recruited into the
cytotoxic process in the Drosophila topoisomerase II
transfected cells. Additional sites of drug action could go
undetected in alkaline elution assays yet still lead to increased
cytotoxicity. The higher etoposide concentration (50 pM) may
be sufficiently cytotoxic so that the contribution of this small
increase in sites of drug action is of little consequence.
Why then was the increase in sensitivity at the low
etoposide concentration lost at 48 h, a time when gene
expression was still evident and when the exogenous
promoter was still functionally turned on (Figure 5)? For
our hypothesis of increased cytotoxicity secondary to
increased production of the target enzyme topoisomerase II
to be operational, the total cellular topo II pool, not just the
exogenous portion, must remain elevated. As shown in
Figures 2 and 3, both the expression and the amount of
endogenous human topo II protein were down-regulated
following induction of the D-topo II gene. Dex treatment had
no effect on the endogenous human topoisomerase II mRNATranhsftion of D4topoU2 into human brain bumour cells
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Table IN Clonogenic survival of HBT20-dTOP2 cells for
doxorubicin. amsacrine and cisplatin
Dex treatment - Dex treatment
Doxorubicin (0.1 pIm) 0.72-+0.06 0.77+--0.05
Amsacrine (1.0ym) 0.67 7 0.04 0.65+0.07
Cisplatin (1.0 sm) 0.75- 0.12 0.69+0.06
Cisplatin (5.0 iMm) 0.47 +0.01 0.44+0.01
Cells were pretreated with or without dexamethasone for 24h. then
incubated with 0.1IMm doxorubicin. 1.0 jum amsacrine or 1 or 5 jum
cisplatin for 2 h. The survival fraction was calculated as described in
Materials and methods. The values are mean +s.d. from two
independent experiments.
Table V Cell cycle analysis in HBT20-parent. HBT20-MAM and HBT20-
dTOP2 cells
Dex G1 phase (00 S-phase °O GjU-phase 00
HBT20-parent (-) 67.3- 6.7 12.5_+4.2 20.2+5.5
65.5-8.5 13.3+-5.5 21.2 5.5
HBT20-MAM (-) 65.9- 5.0 12.9+-5.6 21.2'-5.8
(- ) 65.9- 1.0 12.7-5.7 21.4-5.4
HBT20-dTOP2 (-) 65.4-3.0 13.2-6.1 21.4-3.5
(-) 72.1 - 6.0 13.5-6.0 14.6-5.6
HBT20-parent. HBT20-MAM and HBT20-dTOP' cells were treated either with
or without dexamethasone for 24h. cell cycle analysis was then performed by flow-
cvtometrv as detailed in Materials and methods. Mean- s.d. from three
independent experiments.
or protein levels in the control transfected HBT20-MAM
cells (Figures lb and 3). therefore. this down-regulation was
not merely the result of Dex treatment. The observed
decrease in endogenous topo II mRNA was not associated
with the accumulation of cells in G1 as the percentage of
HBT20-dTOP2 cells in G,, S and G,M was the same as seen
with the HBT20-MAM and HBT20-parent cells (Table V).
Dex treatment also did not alter the cell cvcle time or
distribution of any of the three cell lines. By 24 h of Dex
stimulation, there was significantly less H-topo II protein in
the HBT20-dTOP2 cells than in the HBT20-parent. the
HBT20-MAM or the HBT2O-dTOP2 unstimulated cells
(Figure 3b). The amount of H-topo II protein detected by
Western analysis folloWing 48 h of Dex treatment was further
decreased (data not shown). Therefore. while D-topo II
protein may still result from transcription from the
transfected gene. the amount of total cellular topo II enzyme
(human tDrosophila) may actually be decreased. Less enzyme
provides less target for etoposide interaction, resulting in less
complex formation and decreased cell kill. It is tempting to
speculate that the topo II gene is under tight regulator
control and that a feedback mechanism exists in cells to keep
the product of this gene in balance.
In summar-, we have demonstrated that transfer of a
normal topo II gene into brain tumour cells having a
presumed normal topo II enzyme can increase the sensitivity
of these cells to etoposide. These findings have potential
clinical ramifications, as they indicate that the presence of a
mutated topo II enzyme in the target cell is not necessan- for
this manipulation to increase etoposide responsiveness.
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